HSD17B13 and metabolic dysfunction-associated steatohepatitis: Among them, ARO‐HSD is a GalNAc‐coupled RNAi therapy developed by Arrowhead that selectively targets HSD17B13 mRNA, aiming to downregulate the expression of HSD17B13 to obtain a beneficial LOF effect, and is being developed for the treatment of NASH.225